TCRT - Alaunos Therapeutics, Inc.

2.45
-0.180   -7.347%

Share volume: 63,336
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$2.63
-0.18
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 0%
Dept financing 32%
Liquidity 50%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.58%
1 Month
66.67%
3 Months
42.44%
6 Months
18.36%
1 Year
84.21%
2 Year
308.33%
Key data
Stock price
$2.45
P/E Ratio 
0.00
DAY RANGE
$2.32 - $2.86
EPS 
-$0.82
52 WEEK RANGE
$0.58 - $5.62
52 WEEK CHANGE
$94.44
MARKET CAP 
5.156 M
YIELD 
N/A
SHARES OUTSTANDING 
16.013 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.23
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$30,310
AVERAGE 30 VOLUME 
$1,488,383
Company detail
CEO: Kevin S. Boyle
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.

Recent news
loading